[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-reconstitution\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-reconstitution":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100646819","cmv-cmi-in-cscmvi-after-hsct-100646819",false,"NCT07688759","CMV-CMI in csCMVi After HSCT","Study of CMV Specific Immune Reconstitution in Patients With Clinical Significant CMV Infection After Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)","Inclusion Criteria:\n\n1. ≥18 years old and underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT);\n2. First CMV reactivation after transplantation;\n3. Life expectancy of ≥8 weeks;\n4. The participant (or legally acceptable representative, if applicable) has provided written informed consent for the trial.\n\nExclusion Criteria:\n\n1. Recurrence of CMV infection;\n2. primary CMV infection in CMV-seronegative recipients (R-);\n3. Resistance to known anti-CMV drugs (ganciclovir, valganciclovir, foscarnet, maribavir, etc.);\n4. Currently receiving CMV-CTL treatment or lymphocyte infusion.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","12 Weeks","OBSERVATIONAL","Cytomegalovirus (CMV) reactivation is a common and serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the reconstitution of CMV-specific cell-mediated immunity (CMV-CMI) plays a key role in viral control.\n\nThis prospective, exploratory study will enroll 40 adult CMV-seropositive patients who experience their first CMV reactivation after allo-HSCT. CMV-specific T cell levels (IFN-γ-producing T cells stimulated by IE-1 and pp65 antigens) will be measured using ELISPOT at four time points: at diagnosis of CMV viremia, 3 weeks after initiating preemptive therapy, at anti-CMV drug withdrawal, and 4 weeks after treatment discontinuation. Patients will be followed for 12 weeks after stopping treatment.\n\nThe primary objective is to describe the changes in CMV-specific T cell levels over the therapy. Secondary objectives are to explore the relationship between these levels and the occurrence of refractory CMV infection, recurrent CMV infection, and CMV disease. Findings may help identify patients at high risk of progressing to severe or persistent CMV infection at an early stage of preemptive therapy, enabling personalized intervention strategies.",[25,26,27],"Cytomegalovirus Infections","Hematopoietic Stem Cell Transplantation (HSCT)","Immune Reconstitution",[29,30,31,32],"Cytomegalovirus","Hematopoietic Stem Cell Transplantation","Virus-specific T cells","cell-mediated immunity","RECRUITING","2026-07-03",{"date":36,"type":37},"2026-07-07","ACTUAL",{"date":39,"type":37},"2026-06-01",{"date":41,"type":20},"2028-08-31",{"name":43,"class":44},"The First Affiliated Hospital of Soochow University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":72,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":45},"100608743","high-altitude-hematology-observation-stem-cell-transplantation-halo-sct-100608743","NCT07205523","High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT): A Prospective Real-World Cohort Study in the Qinghai-Tibet Plateau","HALO-SCT","Inclusion Criteria:\n\n1. Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023.\n2. Planned or actual hematopoietic stem cell transplantation (HSCT).\n3. Provision of signed informed consent.\n\nExclusion Criteria:\n\n1. Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons.\n2. Substance abuse compromising adherence.\n3. Any condition judged by investigators to jeopardize safety or compliance.",{"count":55,"type":20},1000,"100 Years","The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.",[26,59,60,61,62,63,64,65,66,67,68,69,70,71,27],"Acute Myeloid Leukemia (AML)","Leukemias, Acute Myeloid","Myeloid Leukemias, Acute","Hemophilia","Myelodysplastic Syndrome","MDS","Lymphoma","Leukemia","Aplastic Anemia","Bleeding Disorders","Bone Marrow Transplantation","Multiple Myeloma","Myeloma, Multiple",[73],"High-altitude Bone marrow transplantation Allogeneic HSCT Autologous HSCT Immune reconstitution Graft-versus-host disease Relapse Survival Quality of life","2025-09-25",{"date":76,"type":37},"2025-10-03",{"date":78,"type":37},"2023-09-01",{"date":80,"type":20},"2100-12-31",{"name":82,"class":44},"Yigeng Cao,MD,PhD",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100601687","the-kinetics-profiling-of-immune-reconstitution-and-clinical-outcomes-100601687","NCT07113730","The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes","Retrospective and Prospective Study on the Kinetics Profiling of Immune Reconstitution and Clinical Outcomes in CMML Following Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Patients with confirmed diagnosis of CMML following HSCT\n2. Patients treated at Peking University People's Hospital since January 1, 2005\n\nExclusion Criteria:\n\n1. Any condition that may render follow-up data unreliable, including but not limited to severe psychiatric disorders\n2. Patients deemed ineligible for the study by investigators",{"count":91,"type":20},300,"Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment. Immune reconstitution (IR) is critical for improving HSCT efficacy and quality of life among survivors, yet its dynamic impact on survival and complications like chronic graft-versus-host disease (cGVHD) in CMML is poorly defined. This study aimed to investigate the dynamics of IR following HSCT in patients with CMML and evaluate its impact on post-transplant clinical outcomes.",[94,27],"Chronic Myelomonocytic Leukemia (CMML)",[94,96,97],"immune reconstitution","allogeneic hematopoietic stem cell transplantation (allo-HSCT)","NOT_YET_RECRUITING","2025-08-11",{"date":101,"type":37},"2025-08-15",{"date":103,"type":20},"2025-08-13",{"date":105,"type":20},"2036-07-31",{"name":107,"class":44},"Peking University People's Hospital"]